UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAPS) UG1

PROJECT SUMMARY Clinical trials are an integral part of MD Anderson Cancer Center’s (MDACC) mission. In FY2023, we cared for approximately 179,000 patients and enrolled more than 9,600 patients on nearly 1,500 interventional studies. MDACC has made significant contributions to the former NCI cooperative groups and the new National Clinical Trial Network (NCTN), including robust trial enrollment, scientific and administrative leadership, and mentoring early career faculty to participate in these important national trials. For FY 2019-2024, at MDACC, 1429 patients were enrolled in NCTN Network group clinical trials, including 1081 patients in therapeutic treatment trials resulting in an average of > 200 patients per year. Centralized coordination of NCTN activities at our institution has facilitated the development and conduct of multidisciplinary, innovative trials. This participation has led to opportunities for service through various NCTN leadership roles. Our institution has also sponsored talented clinical and translational investigators to apply for NCTN membership, provided mentorship of early career faculty, and encouraged applications for NCTN peer-reviewed grant funding. These activities have contributed to the success of the NCTN LAPS UG1 grant as well as working towards the fulfillment of our mission of eliminating cancer in Texas, nationally, and globally through advances in cancer treatment, research and education. Our goals will continue with the supplement request of the NCTN LAPS UG1 grant.